A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 401 participants.

Also called NCT06010004

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 401 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06010004
Other papers using this trial's data
  • Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial The lancet. Diabetes & endocrinology, 2026-10 DOI, PubMed 42607698

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06010004. Randomized; no masking; primary purpose treatment. Start 2023-09-28 (actual); primary completion 2025-06-05 (actual). Results posted on 2026-06-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Long-term Safety Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes
Acronym
ACHIEVE-J
Intervention (Drug)
Orforglipron
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct06010004
Content hash
fa82f62bcb241442d451db5889d8fa99dd2200351be567c1d13ea740b85499c0